NCT06141018View on ClinicalTrials.gov

Effectiveness and Safety of Intra-articular SEMICAL GEL-B CROSS Therapy in Knee Osteoarthritis (SEM-ART1)

NAActive, not recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Knee Osteoarthritis
Interventions
DEVICE

Cross-linked intra-articular hyaluronic acid

Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.

OTHER

Placebo

Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.

Trial Locations (1)

Unknown

Antalya Training and Research Hospital, Antalya

All Listed Sponsors
collaborator

Antalya Training and Research Hospital

OTHER_GOV

lead

Semikal Technology

INDUSTRY

NCT06141018 - Effectiveness and Safety of Intra-articular SEMICAL GEL-B CROSS Therapy in Knee Osteoarthritis (SEM-ART1) | Biotech Hunter | Biotech Hunter